Receptos, located in San Diego California, is a wholly owned subsidiary of Celgene Corporation.


Receptos is focused on the development of therapeutic candidates for the treatment of immune and inflammatory diseases. Receptos' lead program, Ozanimod, is a sphingosine 1-phosphate 1 and 5 receptor small molecule modulator in development for immune-inflammatory indications including relapsing multiple sclerosis (RMS) and inflammatory bowel disease's (Crohn's and Ulcerative Colitis).

Receptos Opportunities Visit


Receptos Pipeline
Receptos Pipeline